New Farm, Australia
New Farm, Australia

Time filter

Source Type

The report "Liver Fibrosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system. Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Companies discussed in this report include  AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc plc, and XTuit Pharmaceuticals Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=966744 . (This report is available at upto 25% Discount till June 02nd 2017.) "Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


The report "Liver Fibrosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system. Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Companies discussed in this report include  AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc plc, and XTuit Pharmaceuticals Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=966744 . (This report is available at upto 25% Discount till June 02nd 2017.) "Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


News Article | May 23, 2017
Site: www.prnewswire.com

LONDON, May 23, 2017 /PRNewswire/ -- Renal Cluster Drug Development Pipeline Review, 2017 Summary This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and also features dormant and discontinued projects. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. There are a total of 39 products in development for this indication, by 28 companies and five academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Pharmaxis, Cellmid and Vascular Biogenics. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. There are a total of 59 products in development for this indication, by 48 companies and two academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals and Vidasym. Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. There are a total of 36 products in development for this indication, by 34 companies and one academic institution. A number of companies are operating in this space, with A1M Pharma alone developing multiple programs within the area. Finally, kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Due to differences between the two patients, an autoimmune reaction against the donor kidney may occur in the recipient. There are a total of 39 products in development for this indication, by 33 companies and two academic institutions. Key companies operating in this pipeline space include Astellas Pharma, GlaxoSmithKline, Hillhurst Biopharmaceuticals and Kyowa Hakko Kirin. While kidney transplant rejection treatments are largely focused on immune system molecular targets such as tumor necrosis factor alpha and complement factors, a range of cellular signaling components are being pursued in the other three key indications, including the activin receptors, cyclin dependent kinases, and growth factor receptors. Scope - Which companies are the most active within the pipeline for renal cluster therapeutics? - Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? - To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? - What are the most important R&D milestones and data publications to have happened in the field of renal cluster therapeutics? Reasons to buy - Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication - Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each - Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these - Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration Download the full report: https://www.reportbuyer.com/product/4910728/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/renal-cluster-drug-development-pipeline-review-2017-300462741.html

Loading Pharmaxis collaborators
Loading Pharmaxis collaborators